Form 4: Catalyst Pharma Director Molly Harper Reports Equity Transactions

Catalyst Pharmaceuticals Director Molly Harper reported the acquisition of stock options and restricted stock units, alongside the vesting and delivery of a tranche of RSUs.

Summary

• Molly Harper, a Director at Catalyst Pharmaceuticals, Inc. (CPRX), reported equity transactions.
• Acquired 18,115 options to purchase common stock at an exercise price of $22.77 on November 20, 2025. These options vest in three equal tranches on November 20, 2026, November 20, 2027, and November 20, 2028, and expire on November 20, 2032.
• Acquired 5,468 Restricted Stock Units (RSUs) on November 20, 2025. These RSUs vest in three equal tranches on November 20, 2026, November 20, 2027, and November 20, 2028, with shares delivered upon vesting.
• On November 21, 2025, 947 Restricted Stock Units (RSUs) vested and were converted into 947 shares of common stock. These specific RSUs were part of a grant that vests in equal tranches on November 21, 2025, November 21, 2026, and November 21, 2027.
• Following these transactions, Ms. Harper beneficially owns 7,693 shares of common stock, 145,389 derivative options, and 149,910 derivative Restricted Stock Units.

Sentiment

Score: 7

Explanation: The filing indicates a director's increased equity stake in the company through stock options and restricted stock units, which is generally viewed positively as it aligns management interests with shareholders. However, it is a routine insider transaction report rather than a performance or strategic announcement.

Positives

• Director Molly Harper increased her beneficial ownership in Catalyst Pharmaceuticals through the acquisition of stock options and Restricted Stock Units, aligning her interests with shareholders.
• The vesting and delivery of 947 shares of common stock to the director indicates a successful conversion of previously granted equity awards.

Future Outlook

NA

Industry Context

NA

Related Party Transactions

• Grant of 18,115 stock options to Director Molly Harper on November 20, 2025, as part of her compensation.
• Grant of 5,468 Restricted Stock Units (RSUs) to Director Molly Harper on November 20, 2025, as part of her compensation.
• Vesting and delivery of 947 shares of common stock from previously granted Restricted Stock Units to Director Molly Harper on November 21, 2025.

Stakeholder Impact

• Shareholders: Potential positive signal due to a director's increased equity alignment with the company's performance.

Next Steps

• Vesting of remaining tranches of 18,115 options on November 20, 2026, November 20, 2027, and November 20, 2028.
• Vesting of remaining tranches of 5,468 Restricted Stock Units on November 20, 2026, November 20, 2027, and November 20, 2028, with shares delivered upon vesting.
• Vesting of remaining tranches of the original grant of 947 Restricted Stock Units on November 21, 2026, and November 21, 2027, with shares delivered within sixty days of vesting.

Key Dates

Keywords

Catalyst Pharmaceuticals, CPRX, Molly Harper, Form 4, Insider Trading, Stock Options, Restricted Stock Units, Equity Compensation, Director Compensation